CyPath Lung sales have increased from the previous quarter, with bioAffinity experiencing significant growth. The growth is attributed to surging demand for CyPath Lung, with test volume more than tripling. Despite this strength, bioAffinity's stock has slipped following the release of its quarterly earnings.